Harrow Posts Strong Q2 Revenue Growth on VEVYE Momentum and Pipeline Expansions — Harrow, Inc.

Event summary

Q2 revenue of $70.7M, up 60% sequentially and 11% YoY.
VEVYE® revenue hit $29.4M, up 58% YoY, with market share doubling to 14.6%.
IHEEZO® unit demand surged 44% sequentially despite reimbursement challenges.
TRIESENCE® recorded its strongest quarter ever, with unit demand up 39% sequentially and 162% YoY.
Acquisition of TYRVAYA® expected to close in H2 2026, adding $30M+ revenue in 2027.

The big picture

Harrow's Q2 results highlight its strategic pivot toward accelerating revenue growth through product launches, acquisitions, and market share gains. The company is positioning itself as a key player in the ophthalmic disease management space, with a focus on expanding its dry eye disease portfolio and retina franchise. The acquisition of TYRVAYA® and the launch of BYOOVIZ® are critical steps in this strategy, but execution risks remain.

What we're watching

Integration Risk: Whether Harrow can successfully integrate TYRVAYA® and BYOOVIZ® into its portfolio without operational disruptions.
Market Share Growth: How VEVYE® will sustain its market share expansion following recent formulary coverage wins.
Execution Pace: The speed at which Harrow can convert built demand into revenue growth and profitability in H2 2026.